Research programme: anti-inflammatory biologics topical - Rogne Bioscience

Drug Profile

Research programme: anti-inflammatory biologics topical - Rogne Bioscience

Alternative Names: C 15; Chemerin 15; RON-2315

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford
  • Developer Rogne Bioscience; University of Oxford
  • Class Peptides
  • Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Interleukin 23 inhibitors; NF-kappa B modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis
  • No development reported Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (Topical)
  • 31 Jul 2014 Anti-inflammatory peptides licensed to Rogne Bioscience worldwide
  • 01 Jan 2014 Preclinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top